Buy, Sell or Hold: Metlife (MET-N)

Home

Daily Stock Opinions and Ratings

Metlife (MET-N)

NYSE:MET

77.21

0.45 (0.58%) 1d

Nervous markets await Nvidia

Investor Insights

This summary was created by AI, based on 1 opinions in the last 12 months.

Metlife (MET-N) appears to be benefitting from a favorable environment due to increasing interest rates, which are typically advantageous for insurance companies. The yield on the stock currently stands at approximately 2.9%, which can provide a stable income stream for investors. However, the growth rate is currently in the single digits, which may be a concern for those seeking more aggressive expansion. Many industry experts suggest that the overall insurance sector is experiencing a favorable tailwind, evidenced by indicators such as the KIE ETF. Investors should consider these dynamics when evaluating Metlife's potential in comparison to its peers, especially in light of the current economic climate.

Consensus

Positive

Valuation

Fair Value

Similar

Aflac Inc, AFL-N

HOLD

Higher rates are actually good for insurance companies. Yield is about 2.9%, growing at single digits and he prefers double-digit growth. The whole industry has a tailwind, and you can see it if you look at the KIE ETF.

DON'T BUY

Does not own shares. Financial services and insurance. Valuation is low and could be good time for investors. Does not own shares. Fundamentally a 6/10. Could be volatile. Better options out there for investors.

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Sep 27/22, Up 7.4%)Stockchase Research Editor: Michael O’Reilly

Our PAST TOP PICK with MET has triggered its stop at $65. To remain disciplined, we recommend covering the position at this time.

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Sep 27/22, Up 27.2%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MET has achieved its target at $77. To remain disciplined, we recommend covering half the position and trailing up the stop loss (from $62) to $67. If triggered, this would result in a net investment gain of 18%.

HOLD

Switch from Canadian insurers to MET? Hit a new high today. Likes it. Financials are at a historical discount. Likes banks, insurers and diversified financials. He wouldn't switch, as some Canadian valuations are quite cheap. Nice dividend of 2.6%.

HOLD

Model price of $87.26, 18% upside. Market really liked its write down on balance sheet or spinoff. Likes it here. Turned itself around. Will probably go to $80, and he'll evaluate it there.

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Sep 27/22, Up 22.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MET is progressing well. To remain disciplined, we now recommend trailing up the stop (from $52.50) to $62.00.

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly This world leader in insurance and benefits is a TOP PICK. The company just announced a deal along with PRU to assume the $16 billion pension obligation of IBM -- right up its alley. We like the value here as the company is trading under book value, just beat analyst earnings expectations, and is projected to trade 7x earnings. It has managed to increase cash reserves, while aggressively retiring debt and buying back shares. Its dividend is backed by a payout ratio under 50% of cash flow. We recommend placing a stop loss at $52.50, looking to achieve $77 -- upside potential of 25%. Yield 3.2% (Analysts’ price target is $77.25)

BUY

The insurers have been in fire, like MetLife. He believes rates will go higher, so definitely stick with them.

DON'T BUY

It's fine, but he does not likes financials (or energy). He just likes MET's yield and that's it.

COMMENT

AIG-N vs. MET-N. AIG-N has been recapitalizing since the disaster of the financial crisis. MET-N did not suffer these issues. The life business is in pretty decent shape but he prefers Canadian lifecos. (Analysts’ price target is $55.57)

BUY

It’s pretty cheap, trading at 8.1 times. Their earnings in July were double year over year and beat expectations. They are growing globally and it’s a safe name with a low valuation. Couldn’t go wrong with this choice in the long term.

WAIT

MET vs. BAC. Dynamics of the two are different, so hard to compare. FMV potential of both is huge. But the market won't go, because interest rates are falling. Aren't any drivers to escalate earnings. Very cheap, but who knows when they're going to pop? (Analysts’ price target is $53.19)

DON'T BUY

The balance sheet is impaired and there should be write-offs, which he hasn't seen. He sees 32% upside with a $64 model price, but he'd be happy seeing this at $53.80. He would recommend this stock above this price. He has recommended MET before, but MET just can't get going. The balance sheet is ugly. Also, if interest rates fall to zero, all insurance companies will get hit.

PAST TOP PICK

(A Top Pick Mar 29/18, Up 3%) Slow or flar growth this and next year, but they are buying back stock. He sees 9% EPS growth this year. Their US retirement portfolio has been doing well. It's cheap at 8x PE and paying almost a 4% dividend. It's been stagnant for many years, but it has tailwinds of lower taxes and volume growth. They're growing in Asia and Europe.

Showing 1 to 15 of 111 entries

Metlife(MET-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 3

Stockchase rating for Metlife is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Metlife(MET-N) Frequently Asked Questions

What is Metlife stock symbol?

Metlife is a American stock, trading under the symbol MET-N on the New York Stock Exchange (MET). It is usually referred to as NYSE:MET or MET-N

Is Metlife a buy or a sell?

In the last year, 3 stock analysts published opinions about MET-N. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Metlife.

Is Metlife a good investment or a top pick?

Metlife was recommended as a Top Pick by on . Read the latest stock experts ratings for Metlife.

Why is Metlife stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Metlife worth watching?

3 stock analysts on Stockchase covered Metlife In the last year. It is a trending stock that is worth watching.

What is Metlife stock price?

On 2025-05-23, Metlife (MET-N) stock closed at a price of $77.21.

Most Recent Experts

Brian Madden

First Avenue Investment Counsel

Stockchase Insights

5i Research

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jim Lebenthal

Cerity Partners

Stephanie Link, Chief investment strategist, Hightower

Hightower

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Metlife (MET-N)

NYSE:MET

Metlife(MET-N)

Metlife(MET-N)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Metlife(MET-N)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Metlife(MET-N)

Metlife(MET-N)

Metlife(MET-N)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Metlife(MET-N)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Metlife(MET-N)

Metlife(MET-N)

Metlife(MET-N)

Metlife(MET-N)

Metlife(MET-N)

Metlife(MET-N)

Metlife(MET-N)

Metlife(MET-N)

Metlife(MET-N) Rating

Metlife(MET-N) Frequently Asked Questions

What is Metlife stock symbol?

Is Metlife a buy or a sell?

Is Metlife a good investment or a top pick?

Why is Metlife stock dropping?

Is Metlife worth watching?

What is Metlife stock price?

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Brian Madden

Stockchase Insights

Jenny Harrington, CEO, Gilman Hill Asset Management

Jim Lebenthal

Stephanie Link, Chief investment strategist, Hightower